Rasagiline 1 mg monotherapy also showed a trend of improvement in emotional well-being compared with placebo (SMD, −1.81; 95% CrI, −3.42 to −0.19) ( Figure 3 ).
← all excerpts
Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis.
1
—
—